(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) Mid-cap biotech Immunovant is judged to be setup especially well for a move higher, by our work. In the throes of a “bearish-to-bullish” reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We’re buyers here. Price Objective: $40+/- This pair of identical charts of Immunovant tell the story: Source: FactSet DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Trending
- IMF chief says no global slowdown in sight yet, but risks are high
- Factbox-What you should know about G7 host town Evian-Les-Bains
- Peru holds rates amid too-close-to-call election
- Bitcoin Price Jumps Above $65K as Trump Announces Official Deal With Iran
- Will the real Kevin Warsh please stand up? Ahead of his first Fed meeting, economists honestly don’t know what to expect.
- Crude oil today: Live updates
- NHL-Hurricanes beat Golden Knights to win Stanley Cup
- Stock futures jump, oil prices fall as Trump says U.S. has reached peace deal with Iran
Monday, June 15
